<DOC>
	<DOCNO>NCT01397890</DOCNO>
	<brief_summary>This multicentre study randomise , parallel group , open-label , 3-month phase IV design ass efficacy tolerability Symbicort add-on treatment Spiriva compare Spiriva alone patient severe chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Efficacy Tolerability Symbicort add-on Treatment Spiriva Compare With Spiriva Alone Patients With Severe Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed date informed consent Men woman patient ≥40 year age Diagnosis COPD symptoms 2 year history least one COPD exacerbation require course oral steroid and/or antibiotic within 112 month Visit 2 Forced Expiratory Volume 1 second ( FEV1 ) ≤50 % predict normal value , prebronchodilator Forced Expiratory Volume 1 second ( FEV1 ) / Forced Vital Capacity ( FVC ) &lt; 70 % , prebronchodilator Total symptom score 2 per day least half runin period ( breathing , cough sputum score diary card ) complete morning recording Digital Peak Flow Meter data least 7 last 10 day runin period A history asthma seasonal allergic rhinitis 40 year age Patients experienced exacerbation COPD require hospitalisation /or emergency room treatment and/or course oral steroid and/or intravenous corticosteroid and/or antibiotic within 4 week prior Visit 2 and/or runin period also patient use systemic glucocorticosteroids ( GCS ) within 4 week and/or inhale GCS within 2 week prior Visit 2 and/or runin period Patients relevant cardiovascular disorder judge investigator Patients glaucoma , prostatic hyperplasia bladderneck obstruction judge investigator Women pregnant , breastfeed childbearing potential judged investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Severe chronic obstructive pulmonary disease ( COPD ) patient</keyword>
</DOC>